<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00248820</url>
  </required_header>
  <id_info>
    <org_study_id>CT02-OV</org_study_id>
    <nct_id>NCT00248820</nct_id>
  </id_info>
  <brief_title>Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses</brief_title>
  <official_title>Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to assess the ability of contrast-enhanced ultrasound in the detection of
      benign and malignant ovarian masses compared to unenhanced ultrasound.

      By using an intravascular contrast agent, this noninvasive and feasible imaging technique
      will allow the investigators to define specific microcirculation patterns in 100 women with
      ovarian lesions.

      The intravascular contrast agent properties will be compared between benign and malignant
      adnexal masses.

      The final purpose of this ultrasonography is to allow the early detection of tumors and to
      improve the characterization between benign and malignant lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SonoVue (Sulphur hexafluoride microbubbles) is a microbubbles preparation that is stable,
      resistant to pressure and specifically designed to be used as a contrast agent for ultrasound
      imaging.

      Study design : one contrast-enhanced ultrasonography is proposed before any surgery to
      patients with ovarian mass.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2002</start_date>
  <completion_date type="Anticipated">February 2009</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>From contrast-enhanced ultrasound: Enhancement parameters derived from time-intensity curves: time-to-peak, enhancement ratio, washout-time</measure>
    <time_frame>inclusion period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histology assessments: microvessel density assessments and histological diagnosis</measure>
    <time_frame>inclusion period</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ovarian Tumor</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Contrast-enhanced ultrasound</intervention_name>
    <description>Contrast enhanced ultrasound using Sonovue / 2.4 ml per injection - one or two injections (maximum of 9.6 ml).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Patient with adnexal mass detected by ultrasound

          -  Any programmed surgery

        Exclusion Criteria:

          -  Any contraindication to surgery

          -  Injection of another contrast agent within 24 hours before the study examination

          -  Pregnancy, breastfeeding

          -  Patient known to have a coronary syndrome

          -  Unstable angina and myocardial infarction

          -  Acute cardiac failure, Class III/IV cardiac failure

          -  Severe rhythm disorders

          -  Acute endocarditis

          -  Prosthetic valves

          -  Patient previously having received an investigational drug within 30 days prior to
             admission into this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henri Marret, PR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Gynécologie Obstétrique - Centre Olympe de Gouges CHRU Tours</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Tranquart, PR</last_name>
    <role>Study Director</role>
    <affiliation>Centre d'Innovation Technologique - CHRU Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henri Marret, PR</last_name>
    <phone>(33) 0 47 47 82 59</phone>
    <email>marret@med.univ-tours.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri Marret, PR</last_name>
      <phone>(33) 0 47 47 82 59</phone>
      <email>marret@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>François Tranquart, PR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Tailor A, Jurkovic D, Bourne TH, Collins WP, Campbell S. Sonographic prediction of malignancy in adnexal masses using multivariate logistic regression analysis. Ultrasound Obstet Gynecol. 1997 Jul;10(1):41-7.</citation>
    <PMID>9263422</PMID>
  </reference>
  <reference>
    <citation>MacSweeney JE, Cosgrove DO, Arenson J. Colour Doppler energy (power) mode ultrasound. Clin Radiol. 1996 Jun;51(6):387-90. Review.</citation>
    <PMID>8654001</PMID>
  </reference>
  <reference>
    <citation>Timmerman D, Bourne TH, Tailor A, Collins WP, Verrelst H, Vandenberghe K, Vergote I. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model. Am J Obstet Gynecol. 1999 Jul;181(1):57-65.</citation>
    <PMID>10411796</PMID>
  </reference>
  <reference>
    <citation>Kinkel K, Hricak H, Lu Y, Tsuda K, Filly RA. US characterization of ovarian masses: a meta-analysis. Radiology. 2000 Dec;217(3):803-11.</citation>
    <PMID>11110947</PMID>
  </reference>
  <reference>
    <citation>Suren A, Osmers R, Kulenkampff D, Kuhn W. Visualization of blood flow in small ovarian tumor vessels by transvaginal color Doppler sonography after echo enhancement with injection of Levovist. Gynecol Obstet Invest. 1994;38(3):210-2.</citation>
    <PMID>8001878</PMID>
  </reference>
  <reference>
    <citation>Ordén MR, Gudmundsson S, Kirkinen P. Contrast-enhanced sonography in the examination of benign and malignant adnexal masses. J Ultrasound Med. 2000 Nov;19(11):783-8. Erratum in: J Ultrasound Med 2001 Jan;20(1):20.</citation>
    <PMID>11065267</PMID>
  </reference>
  <reference>
    <citation>Morel DR, Schwieger I, Hohn L, Terrettaz J, Llull JB, Cornioley YA, Schneider M. Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging. Invest Radiol. 2000 Jan;35(1):80-5.</citation>
    <PMID>10639039</PMID>
  </reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2005</study_first_submitted>
  <study_first_submitted_qc>November 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2005</study_first_posted>
  <last_update_submitted>November 21, 2007</last_update_submitted>
  <last_update_submitted_qc>November 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2007</last_update_posted>
  <keyword>Contrast-enhanced Ultrasound</keyword>
  <keyword>Ultrasound Contrast agent, microbubbles</keyword>
  <keyword>Ovarian tumor</keyword>
  <keyword>vascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

